GABA levels in CSF of patients with psychiatric disorders

Back to table of contents Previous article Next article No AccessGABA levels in CSF of patients with psychiatric disordersPublished Online:1 Apr 2006https://doi.org/10.1176/ajp.137.3.362AboutSectionsView articleAbstractPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail View articleAbstractThe authors measured gamma-aminobutyric acid (GABA) levels in the lumbar CSF of patients with depression, with psychosis, or undergoing evaluation for a neurologic disorder. GABA levels in the CSF from depressed patients were significantly decreased compared with neurologic control patients. CSF GABA levels in psychotic patients were not different from those in neurologic patients, although the data suggested a decrease in CSF GABA levels in patients with schizoaffective disorder. Access content To read the fulltext, please use one of the options below to sign in or purchase access. Personal login Institutional Login Sign in via OpenAthens Register for access Purchase Save for later Item saved, go to cart PPV Articles - American Journal of Psychiatry $35.00 Add to cart PPV Articles - American Journal of Psychiatry Checkout Please login/register if you wish to pair your device and check access availability. Not a subscriber? Subscribe Now / Learn More PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development. Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.). FiguresReferencesCited byDetailsCited byEfficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study24 October 2023 | Neuropsychopharmacology, Vol. 49, No. 2Efficacy and safety of zuranolone for the treatment of depression: A systematic review and meta-analysisPsychiatry Research, Vol. 331Promising new pharmacological targets for depression: The search for efficacyDrug Discovery Today, Vol. 28, No. 12The efficacy and safety of some new GABAkines for treatment of depression: A systematic review and meta-analysis from randomized controlled trialsPsychiatry Research, Vol. 328Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo‐Controlled Phase 3 TrialAnita H. Clayton, M.D., Robert Lasser, M.D., M.B.A., Sagar V. Parikh, M.D., Dan V. Iosifescu, M.D., JungAh Jung, Ph.D., Mona Kotecha, M.D., Fiona Forrestal, M.Sc., Jeffrey Jonas, M.D., Stephen J. Kanes, M.D., Ph.D., James Doherty, Ph.D.3 May 2023 | American Journal of Psychiatry, Vol. 180, No. 9GABA-ergic Modulators: New Therapeutic Approaches to Premenstrual Dysphoric Disorder5 August 2023 | CNS Drugs, Vol. 37, No. 8Medial Frontal Cortex GABA Concentrations in Psychosis Spectrum and Mood Disorders: A Meta-analysis of Proton Magnetic Resonance Spectroscopy StudiesBiological Psychiatry, Vol. 93, No. 2GABA System in Depression: Impact on Pathophysiology and PsychopharmacologyCurrent Medicinal Chemistry, Vol. 29, No. 36Depressive-like behaviors induced by chronic cerebral hypoperfusion associate with a dynamic change of GABAB1/B2 receptors expression in hippocampal CA1 regionPhysiology & Behavior, Vol. 254The Development of GABAergic Network in Depression in Recent 17 Years: A Visual Analysis Based on CiteSpace and VOSviewer18 May 2022 | Frontiers in Psychiatry, Vol. 13Somatostatin and Somatostatin-Containing Interneurons—From Plasticity to Pathology15 February 2022 | Biomolecules, Vol. 12, No. 2Large-Scale Transcriptomics Studies Provide Insight Into Sex Differences in DepressionBiological Psychiatry, Vol. 91, No. 1Ventromedial prefrontal cortex/anterior cingulate cortex Glx, glutamate, and GABA levels in medication-free major depressive disorder5 August 2021 | Translational Psychiatry, Vol. 11, No. 1A Selective Review of the Excitatory-Inhibitory Imbalance in Schizophrenia: Underlying Biology, Genetics, Microcircuits, and Symptoms21 October 2021 | Frontiers in Cell and Developmental Biology, Vol. 9TMS-EEG: An emerging tool to study the neurophysiologic biomarkers of psychiatric disordersNeuropharmacology, Vol. 197Inhibitory and excitatory neurotransmitter systems in depressed and healthy: A positron emission tomography and magnetic resonance spectroscopy studyPsychiatry Research: Neuroimaging, Vol. 315Stress-Related Dysfunction of Adult Hippocampal Neurogenesis—An Attempt for Understanding Resilience?8 July 2021 | International Journal of Molecular Sciences, Vol. 22, No. 14Glutamate and GABA Homeostasis and Neurometabolism in Major Depressive Disorder27 April 2021 | Frontiers in Psychiatry, Vol. 12Number Needed to Treat and Number Needed to Harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorderJournal of Affective Disorders, Vol. 285Concomitant lorazepam use and antidepressive efficacy of repetitive transcranial magnetic stimulation in a naturalistic setting9 July 2020 | European Archives of Psychiatry and Clinical Neuroscience, Vol. 271, No. 1Systematic review of biological markers of therapeutic repetitive transcranial magnetic stimulation in neurological and psychiatric disordersClinical Neurophysiology, Vol. 132, No. 2Altered GABA-mediated information processing and cognitive dysfunctions in depression and other brain disorders28 April 2020 | Molecular Psychiatry, Vol. 26, No. 1Synaptic inhibition in the neocortex: Orchestration and computation through canonical circuits and variations on the themeCortex, Vol. 132Brexanolone and postpartum depression: what does it have to do with GABA?13 July 2019 | Archives of Women's Mental Health, Vol. 22, No. 6Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel TreatmentsNeuron, Vol. 102, No. 1Altered Transcranial Magnetic Stimulation–Electroencephalographic Markers of Inhibition and Excitation in the Dorsolateral Prefrontal Cortex in Major Depressive DisorderBiological Psychiatry, Vol. 85, No. 6Acta Neuropsychiatrica, Vol. 31, No. 1Frontiers in Cellular Neuroscience, Vol. 13A review of the neurobiological underpinning of comorbid substance use and mood disordersJournal of Affective Disorders, Vol. 241Molecular Psychiatry, Vol. 23, No. 5Biological Psychiatry, Vol. 82, No. 8Molecular biomarkers of depressionNeuroscience & Biobehavioral Reviews, Vol. 64A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder18 August 2015 | Molecular Psychiatry, Vol. 21, No. 3Pharmacological Reports, Vol. 68, No. 2Psychoneuroendocrinology, Vol. 73The dose makes the poison: from glutamate-mediated neurogenesis to neuronal atrophy and depressionReviews in the Neurosciences, Vol. 27, No. 6GABAA receptor-acting neurosteroids: A role in the development and regulation of the stress responseFrontiers in Neuroendocrinology, Vol. 36Why are cortical GABA neurons relevant to internal focus in depression? A cross-level model linking cellular, biochemical and neural network findings22 July 2014 | Molecular Psychiatry, Vol. 19, No. 9Depression and Anxiety, Vol. 31, No. 10Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 53Altered GABA function in Major Depression29 July 2014Journal of Neural Transmission, Vol. 120, No. 6Journal of Neuroimmunology, Vol. 255, No. 1-2International Journal of Neuropsychopharmacology, Vol. 16, No. 8Beneficial Effects of Garlic Components on Neurological Disorders26 May 2012Neuropsychopharmacology, Vol. 37, No. 6Corticotropin-Releasing Hormone, Glutamate, and γ-Aminobutyric Acid in Depression16 March 2010 | The Neuroscientist, Vol. 17, No. 1Neuroscience & Biobehavioral Reviews, Vol. 35, No. 3Pharmacology Biochemistry and Behavior, Vol. 97, No. 4Journal of Nutritional Science and Vitaminology, Vol. 57, No. 1European Journal of Nuclear Medicine and Molecular Imaging, Vol. 37, No. 3Biological Psychiatry, Vol. 67, No. 5Depression30 October 2009Depression: Phenomenology, Epidemiology, and Pathophysiology17 August 2010Life Sciences, Vol. 85, No. 23-26Toxicology Letters, Vol. 185, No. 3Neuropsychopharmacology, Vol. 34, No. 3Journal of Psychiatric Research, Vol. 42, No. 5Pharmacology Biochemistry and Behavior, Vol. 90, No. 2Cellular and Molecular Neurobiology, Vol. 27, No. 5Neuroscience, Vol. 148, No. 3Expert Opinion on Drug Discovery, Vol. 2, No. 10, Vol. 73Biological Psychiatry, Vol. 59, No. 5Brain Research, Vol. 1090, No. 1Pharmacology Biochemistry and Behavior, Vol. 84, No. 4Repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex and cortical excitability in patients with major depressive disorderExperimental Neurology, Vol. 196, No. 2Potential use of neurosteroids and neuroactive steroids as modulators of symptoms of depression, anxiety, and psychotic disorders12 December 2005 | Drug Development Research, Vol. 65, No. 4Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 29, No. 2Schizophrenia Research, Vol. 72, No. 2-3Journal of Interferon & Cytokine Research, Vol. 25, No. 4NeuroRX, Vol. 2, No. 4GABAergic dysfunction in mood disorders30 July 2003 | Molecular Psychiatry, Vol. 8, No. 8Biological Psychiatry, Vol. 54, No. 8Parental Depression: Animal Models of an Adverse Life EventD. Jeffrey Newport, M.D., M.Div., Zachary N. Stowe, M.D., and Charles B. Nemeroff, M.D., Ph.D.1 August 2002 | American Journal of Psychiatry, Vol. 159, No. 8The comorbidity of bipolar and anxiety disorders: prevalence, psychobiology, and treatment issuesJournal of Affective Disorders, Vol. 68, No. 1Pharmacology Biochemistry and Behavior, Vol. 67, No. 1Psychoneuroendocrinology, Vol. 24, No. 2Life Sciences, Vol. 63, No. 15Psychiatric Clinics of North America, Vol. 21, No. 2Immunopharmacology and Immunotoxicology, Vol. 20, No. 2Neuroscience Research, Vol. 29, No. 1Inhibitory actions of the antidepressant/antipanic drug phenelzine on brain GABA transaminaseArchives of Pharmacal Research, Vol. 19, No. 6Journal of Affective Disorders, Vol. 34, No. 4Neuroscience Letters, Vol. 176, No. 1Neuroscience, Vol. 58, No. 3Baclofen-induced growth hormone release in major depression: relationship to dexamethasone suppression test result1 April 2006 | American Journal of Psychiatry, Vol. 150, No. 11Repeated administration of desipramine and a GABA B receptor antagonist, CGP 36742, discretely up‐regulates GABA B receptor binding sites in rat frontal cortex19 July 2012 | British Journal of Pharmacology, Vol. 110, No. 2Brain Research, Vol. 631, No. 1Journal of Neurology, Neurosurgery & Psychiatry, Vol. 56, No. 8GABA receptor alterations after chronic lithium administration. Comparison with carbamazepine and sodium valproateProgress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 16, No. 4Effect of Antidepressants on Neurotransmission: a Common Mechanism of Action?Journal of Neural Transmission, Vol. 90, No. 3Biological Psychiatry, Vol. 32, No. 4General Pharmacology: The Vascular System, Vol. 23, No. 2Clinical and biochemical aspects of depressive disorders: II. Transmitter/receptor theories12 October 2004 | Synapse, Vol. 9, No. 4Fengabine in depression: A placebo‐controlled study of a GABA agonist13 October 2004 | Human Psychopharmacology: Clinical and Experimental, Vol. 6, No. 2Brain Research, Vol. 545, No. 1-2Psychoneuroendocrinology, Vol. 16, No. 6Psychological Medicine, Vol. 21, No. 3Journal of Affective Disorders, Vol. 18, No. 1General Pharmacology: The Vascular System, Vol. 21, No. 4GABAB receptors are up-regulated by chronic treatment with lithium or carbamazepine. GABA hypothesis of affective disorders?European Journal of Pharmacology, Vol. 166, No. 1CSF GABA in caregiver spouses of Alzheimer patients1 April 2006 | American Journal of Psychiatry, Vol. 146, No. 6Biological Psychiatry, Vol. 25, No. 7Brain Research Reviews, Vol. 14, No. 3Journal of Epilepsy, Vol. 2, No. 4Alpha 2 agonists and GABAergic agents reverse isoniazid‐induced convulsions in mice6 March 2008 | Drug Development Research, Vol. 17, No. 2Changes in central GABAergic function following acute and repeated stress19 July 2012 | British Journal of Pharmacology, Vol. 93, No. 3Effects of chronic oral administration of the antidepressants, desmethylimipramine and zimelidine on rat cortical GABA B binding sites: a comparison with 5‐HT 2 binding site changes19 July 2012 | British Journal of Pharmacology, Vol. 93, No. 2ChroNc Treatment with Lithium Chloride: Reduced Number of GABA Receptors in Frontal Cortex of Rat Brain25 March 2009 | Pharmacology & Toxicology, Vol. 62, No. 2Biological Psychiatry, Vol. 23, No. 2Brain Research, Vol. 463, No. 1Brain Research, Vol. 460, No. 1Journal of Psychiatric Research, Vol. 22, No. 3Journal of the Neurological Sciences, Vol. 87, No. 2-3Pharmacology Biochemistry and Behavior, Vol. 29, No. 2Psychiatry Research, Vol. 26, No. 2New England Journal of Medicine, Vol. 319, No. 6Psychoneuroendocrinology, Vol. 12, No. 1On the central effects of the GABA agonist fengabine: Psychometric and pharmaco‐EEG studies utilizing imaging methods6 March 2008 | Drug Development Research, Vol. 11, No. 3-4Cerebrospinal fluid GABA and homocarnosine concentrations in patients with Friedreich's ataxia, Parkinson's disease, and Huntington's chorea12 October 2004 | Movement Disorders, Vol. 2, No. 2Neurotransmitter receptors, endocrine responses and the biological substrates of depression: A review13 October 2004 | Human Psychopharmacology: Clinical and Experimental, Vol. 1, No. 1Dosage, Seizure Threshold, and the Antidepressant Efficacy of Electroconvulsive Therapya16 December 2006 | Annals of the New York Academy of Sciences, Vol. 462, No. 1Effects of Lithium on Brain MetabolismBiological Psychiatry, Vol. 21, No. 7Biological Psychiatry, Vol. 21, No. 8-9European Journal of Pharmacology, Vol. 121, No. 2Pharmacology Biochemistry and Behavior, Vol. 25, No. 5Archives of Gerontology and Geriatrics, Vol. 5, No. 3Biological Aspects of Depression: A Review of The Etiology and Mechanisms of Action and Clinical Assessment of AntidepressantsValproate as psychotropic agent23 August 2007 | Acta Psychiatrica Scandinavica, Vol. 72, No. 3Neurochemical Aspects of SchizophreniaPsychopharmacology, Vol. 87, No. 2Neuropharmacology, Vol. 24, No. 3Psychoneuroendocrinology, Vol. 10, No. 4Medical Hypotheses, Vol. 18, No. 4CURRENT STATUS OF THE BIOGENIC AMINE THEORY OF DEPRESSIONPathological Neurochemistry of Cerebrospinal FluidGABA receptor agonists: Pharmacological spectrum and therapeutic actions22 September 2006 | Medicinal Research Reviews, Vol. 5, No. 1CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls1 April 2006 | American Journal of Psychiatry, Vol. 141, No. 12Brain Research, Vol. 307, No. 1-2Journal of Psychiatric Research, Vol. 18, No. 4Life Sciences, Vol. 35, No. 21Journal of Affective Disorders, Vol. 6, No. 2Etiology and treatment of childhood depression: A biopsychological perspectiveComprehensive Psychiatry, Vol. 24, No. 5Effects of Subchronic Treatment of Methamphetamine Haloperidol on the Rat Brain Levels of GABA, Glutamate and Aspartate17 March 2008 | Psychiatry and Clinical Neurosciences, Vol. 37, No. 1Human CSF GABA Concentrations: Revised Dowd for Controls, but Not Decreased in Huntington's Chorea5 October 2006 | Journal of Neurochemistry, Vol. 38, No. 3Pharmaceutisch Weekblad Scientific Edition, Vol. 4, No. 5Psychiatry Research, Vol. 6, No. 3Psychiatry Research, Vol. 7, No. 2General Pharmacology: The Vascular System, Vol. 13, No. 2Psychological Medicine, Vol. 12, No. 1Behavioral and Brain Sciences, Vol. 5, No. 1Behavioral and Brain Sciences, Vol. 5, No. 1Behavioral and Brain Sciences, Vol. 5, No. 1Behavioral and Brain Sciences, Vol. 5, No. 1Behavioral and Brain Sciences, Vol. 5, No. 1Behavioral and Brain Sciences, Vol. 5, No. 1Behavioral and Brain Sciences, Vol. 5, No. 1Behavioral and Brain Sciences, Vol. 5, No. 1Behavioral and Brain Sciences, Vol. 5, No. 1Behavioral and Brain Sciences, Vol. 5, No. 1Behavioral and Brain Sciences, Vol. 5, No. 1Behavioral and Brain Sciences, Vol. 5, No. 1Behavioral and Brain Sciences, Vol. 5, No. 1Behavioral and Brain Sciences, Vol. 5, No. 1Behavioral and Brain Sciences, Vol. 5, No. 1Behavioral and Brain Sciences, Vol. 5, No. 1Behavioral and Brain Sciences, Vol. 5, No. 1Behavioral and Brain Sciences, Vol. 5, No. 1Behavioral and Brain Sciences, Vol. 5, No. 1Behavioral and Brain Sciences, Vol. 5, No. 1Behavioral and Brain Sciences, Vol. 5, No. 1Behavioral and Brain Sciences, Vol. 5, No. 1Behavioral and Brain Sciences, Vol. 5, No. 1Behavioral and Brain Sciences, Vol. 5, No. 1Behavioral and Brain Sciences, Vol. 5, No. 1Behavioral and Brain Sciences, Vol. 5, No. 1Behavioral and Brain Sciences, Vol. 5, No. 1Behavioral and Brain Sciences, Vol. 5, No. 1Behavioral and Brain Sciences, Vol. 5, No. 1GABA in Cerebrospinal Fluid of Children with Febrile Convulsions5 November 2007 | Epilepsia, Vol. 22, No. 6γ‐Aminobutyric Acid Concentration in Cerebrospinal Fluid in Schizophrenia5 October 2006 | Journal of Neurochemistry, Vol. 36, No. 4Molecular and Cellular Biochemistry, Vol. 39, No. 1Journal of Affective Disorders, Vol. 3, No. 4Cerebrospinal Fluid Studies of Neurotransmitter Function in Manic and Depressive Illness Volume 137Issue 3 March 1980Pages 362-364 Metrics PDF download History Published online 1 April 2006 Published in print 1 March 1980